Literature DB >> 8956632

A comparative study of the effects of timolol and latanoprost on blood flow velocity of the retrobulbar vessels.

M T Nicolela1, A R Buckley, B E Walman, S M Drance.   

Abstract

PURPOSE: To examine the effects of topical timolol and latanoprost on retrobulbar vessel blood velocity in patients with glaucoma or ocular hypertension.
METHODS: Nine patients with primary open-angle glaucoma and six patients with ocular hypertension were enrolled for this study. All patients were treated topically with 0.5% timolol or 0.005% latanoprost, using a double-masked crossover design with a 3-week washout before administration of each drug. Each patient had a baseline color Doppler imaging ultrasound of the central retinal artery, short posterior ciliary arteries, and ophthalmic artery and two other ultrasound examinations during the 1-week treatment with each drug, performed 12 hours after the first dose of the drug and 12 hours after the last dose, 7 days later.
RESULTS: Both topical timolol and topical latanoprost significantly reduced the intraocular pressure. The only significant change observed in the retrobulbar blood velocity with timolol was a reduction of end diastolic velocity in the ophthalmic artery 12 hours after the first dose, accompanied by a trend toward a decrease in the peak systolic velocity and an increase in the resistance index in the same vessel. No change in blood velocity was observed with latanoprost.
CONCLUSION: Topical timolol and latanoprost significantly reduced the intraocular pressure in ocular hypertensive and glaucoma patients without creating substantial hemodynamic changes in the retrobulbar vessels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8956632     DOI: 10.1016/s0002-9394(14)70374-5

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  14 in total

Review 1.  Effects of antiglaucoma drugs on blood flow of optic nerve heads and related structures.

Authors:  Chihiro Mayama; Makoto Araie
Journal:  Jpn J Ophthalmol       Date:  2013-01-16       Impact factor: 2.447

Review 2.  Topical drug therapy in glaucoma.

Authors:  Hemma Resch; Gerhard Garhofer
Journal:  Wien Med Wochenschr       Date:  2006-09

Review 3.  A preliminary risk-benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension.

Authors:  D L Eisenberg; C B Camras
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

4.  Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension.

Authors:  W Y Zhang; A L Po; H S Dua; A Azuara-Blanco
Journal:  Br J Ophthalmol       Date:  2001-08       Impact factor: 4.638

5.  A comparative study on the effects of apraclonidine and timolol on the ophthalmic blood flow velocity waveforms.

Authors:  S Oruç; E C Sener
Journal:  Int Ophthalmol       Date:  1999       Impact factor: 2.031

6.  Effect of latanoprost 0.005% and brimonidine tartrate 0.2% on pulsatile ocular blood flow in normal tension glaucoma.

Authors:  C Jui-Ling Liu; Y-C Ko; C-Y Cheng; J C Chou; W-M Hsu; J-H Liu
Journal:  Br J Ophthalmol       Date:  2002-11       Impact factor: 4.638

Review 7.  Prostaglandin analogues in the treatment of glaucoma.

Authors:  C Lindén; A Alm
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

8.  Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension.

Authors:  Anne J Lee; Peter McCluskey
Journal:  Clin Ophthalmol       Date:  2010-07-30

9.  The effect of latanoprost on ocular blood flow.

Authors:  Alon Harris; Hanna J Garzozi; Lynne McCranor; Ehud Rechtman; Chi-Wah Yung; Brent Siesky
Journal:  Int Ophthalmol       Date:  2008-02-23       Impact factor: 2.031

10.  Effect of bimatoprost on ocular circulation in patients with open-angle glaucoma or ocular hypertension.

Authors:  Cengiz Akarsu; Sevda Yilmaz; Pelin Taner; Ahmet Ergin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-04-07       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.